Sapience Therapeutics
Latest round
- Series B
Last raised
- May 2022
Total raised
- $64M
Investors
- 6
About Sapience Therapeutics
Sapience Therapeutics, Inc. focuses on developing innovative peptide therapeutics for oncology, targeting challenging cancer types through advanced treatments.Sapience Therapeutics, Inc. specializes in peptide therapeutics for cancer treatment. Founded in 2015, the company is based in the US and has not undergone any notable pivots. The firm was founded by Barry Kappel, who also serves as the CEO.Sapience Therapeutics specializes in the development of innovative peptide therapeutics aimed at oncology treatment. Their core product offerings include SPEARs™ (therapeutic peptides that act inside cancer cells) and SPARCs™ (therapeutic peptides that target the exterior of cancer cells). Notable products in their pipeline include lucicebtide (formerly known as ST101) and ST316, both of which are currently in Phase 2 clinical trials. These products are designed to target traditionally elusive oncogenic proteins, addressing unmet medical needs in conditions such as glioblastoma and colorectal cancer.Sapience Therapeutics generates revenue through collaborations and partnerships in the biotechnology and pharmaceutical sectors, particularly in relation to their proprietary peptide therapeutics. Transactions typically occur within a framework of clinical trial partnerships, where healthcare institutions and research organizations may engage in agreements to evaluate the efficacy of Sapience's lead products. The pricing structure is based on contractual agreements tied to the advancement of their clinical trials and the commercialization of their products, especially the trademarked SPEARs™ and SPARCs™. The company aims to launch new products, with a focus on enhancing their offerings in oncology treatment. Additionally, they are targeting expansion into new geographical markets, with specific plans to reach additional regions in North America and Europe. Their strategic initiatives are set to further their clinical trials and product development in the coming years.
Who invested in Sapience Therapeutics
6 investors across 2 rounds
See all investors in Sapience Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sapience Therapeutics
Who invested in Sapience Therapeutics?
Sapience Therapeutics has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sapience Therapeutics raised?
Sapience Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Sapience Therapeutics last raise money?
Sapience Therapeutics's most recent round on record is a Series B, in May 2022.
What does Sapience Therapeutics do?
Sapience Therapeutics is a biotechnology company.
Where is Sapience Therapeutics headquartered?
Sapience Therapeutics is headquartered in US.
Which VCs invest in companies like Sapience Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Sapience Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Sapience Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.